Financials
Financial year 2025
LAVISTA PHARMA from Courcelles, company number BE0816918063, closed financial year 2025 with a result of € 153,210 after tax. For that financial year LAVISTA PHARMA recorded a gross margin of € 693,603 and equity of € 789,600. Compared with financial year 2024, the result moved from € 161,709 to € 153,210. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 789,600
▲ 24% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 153,210
▼ 5% vs 2024
Profit after tax over the fiscal year.
€ 12,841
▼ 34% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 749,600.
People and assets in 2025
7.2
▲ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 359,170
▲ 4% vs 2024
€ 49,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 68,638
▲ 34% vs 2024
Of which on lease € 26,542.
Debts at end 2025
€ 1.1 million
▲ 16% vs 2024
€ 230,319 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 345,779
▲ 48% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 49,832
▲ 9% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 402,833 | € 432,915 | € 658,032 | € 693,603 | ▲ 5% |
| Profit after taxes | € 9,420 | € -13,250 | € 161,709 | € 153,210 | ▼ 5% |
| Equity | € 637,931 | € 624,681 | € 636,390 | € 789,600 | ▲ 24% |
| Total debts | € 541,329 | € 1,141,213 | € 1,419,812 | € 1,684,533 | ▲ 19% |
| Cash | € 70,335 | € 17,024 | € 19,597 | € 12,841 | ▼ 34% |
| Land & buildings | € 94,295 | € 86,767 | € 96,571 | € 87,741 | ▼ 9% |
| Retained profit | € 597,931 | € 584,681 | € 596,390 | € 749,600 | ▲ 26% |
| Dividend | € 0 | € 0 | € 150,000 | € 0 | ▼ 100% |
| Bank debt | € 409,144 | € 949,095 | € 974,296 | € 1,130,302 | ▲ 16% |
| Balance sheet total | € 1,179,261 | € 1,765,894 | € 2,056,202 | € 2,474,133 | ▲ 20% |
| Employees (FTE) | 5.6 | - | 6.8 | 7.2 | ▲ 0.4 |
Key figures of LAVISTA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LAVISTA PHARMA?
What happened at LAVISTA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 153,210 (▼ 5% vs 2024). filed late Source: NBB ↗
- New establishment in Courcelles. KBO
- Start of the company according to the CBE. KBO
In short
From € 9,420 profit in 2022 to € 153,210 profit in 2025.
Paid € 110,261 in corporate taxes since 2022.
Best year ever: 2024, with € 161,709 profit.
On average € 96,300 of value added per employee in 2025.
A new publication or filing at LAVISTA PHARMA? We notify you, reason included.
Follow LAVISTA PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind LAVISTA PHARMA is VICTOR STAQUET LAURENT. It owns 68% of Pharmacie François itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Rue Fontaine de la Justice 2
6181 Courcelles
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0816.918.063
- VAT number
- BE 0816.918.063
- Registered office
- Rue Fontaine de la Justice 2, 6181 Courcelles
- Names & denominations
- LAVISTA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 July 2009
- Peppol
- Active · Active since 12 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings